NCT00002129已完成1 期
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
研究概览
简要总结
To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.
详细描述
Twelve patients per dose level receive vesnarinone at 1 of 3 doses for 12 weeks. At least six patients at a given dose level must have completed 2 weeks of treatment before dose is escalated in subsequent patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002131Otsuka America Pharmaceutical28
已完成
1 期
A Study of Multiple Doses of Vesnarinone in Advanced HIV DiseaseHIV InfectionsNCT00002337Otsuka America Pharmaceutical56
已完成
不适用
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected PersonsHIV InfectionsNCT00002130Otsuka America Pharmaceutical
已完成
1 期
A Study of CI-1012 in HIV-Infected PatientsHIV InfectionsNCT00002196Parke-Davis32
Unknown
1 期
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1HIVNCT02390466InnaVirVax15